---
layout: default
title: Isosorbide Dinitrate
description: "Isosorbide Dinitrate çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚é«˜è­‰æ“šç­‰ç´š L2ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: é«˜è­‰æ“šç­‰ç´š (L1-L2)
nav_order: 95
evidence_level: L1
indication_count: 10
---

# Isosorbide Dinitrate

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L2</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Isosorbide Dinitrateï¼šå¾ ç‹¹å¿ƒç—‡ åˆ° è‚ºé«˜å£“

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Isosorbide Dinitrate å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Isosorbide dinitrateï¼ˆäºŒç¡é…¸ç•°å±±æ¢¨é…¯ï¼‰æ˜¯ä¸€ç¨®æœ‰æ©Ÿç¡é…¸é…¯é¡è¡€ç®¡æ“´å¼µåŠ‘ï¼Œç”¨æ–¼é é˜²å’Œæ²»ç™‚ç‹¹å¿ƒç—‡ã€‚TxGNN æ¨¡å‹é æ¸¬å®ƒå°**è‚ºé«˜å£“ (pulmonary hypertension)** æœ‰æ½›åœ¨æ²»ç™‚æ•ˆæœï¼Œç›®å‰æœ‰è¶…é **20 ç¯‡æ–‡ç»**æ”¯æŒæ­¤é æ¸¬ï¼Œè­‰æ“šç­‰ç´šé«˜ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | é é˜²åŠæ²»ç™‚ç‹¹å¿ƒç—‡ç™¼ä½œã€å† ç‹€å‹•è„ˆä¸å…¨ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | è‚ºé«˜å£“ (pulmonary hypertension)ã€è„«é«®ç—‡ (alopecia) |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.98% (è‚ºé«˜å£“) |
| è­‰æ“šç­‰ç´š | L2 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | å¤šå¼µ |
| å»ºè­°æ±ºç­– | Explore |



## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. alopecia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p><p class="key-answer" data-question="é€™å€‹è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰æ˜¯ä»€éº¼ï¼Ÿ"></p>
<p>Isosorbide dinitrate é€šéé‡‹æ”¾ä¸€æ°§åŒ–æ°®ï¼ˆNOï¼‰æ¿€æ´»è¡€ç®¡å¹³æ»‘è‚Œç´°èƒä¸­çš„é³¥è‹·é…¸ç’°åŒ–é…¶ï¼Œå°è‡´ç’°ç£·é…¸é³¥è‹·ï¼ˆcGMPï¼‰æ¿ƒåº¦å‡é«˜ï¼Œé€²è€Œå¼•èµ·è¡€ç®¡èˆ’å¼µã€‚</p>
<p></p></p>

<p><div class="key-takeaway"></p>
<p>æ­¤é æ¸¬åŸºæ–¼è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰ï¼Œèˆ‡ç¾æœ‰è‡¨åºŠè­‰æ“šæ–¹å‘ä¸€è‡´ã€‚</p>

<h3>è‡¨åºŠè©¦é©—</h3>

<p>é›–ç„¡å°ˆé–€é‡å°è‚ºé«˜å£“çš„å¤§å‹ RCT ç™»è¨˜ï¼Œä½†æ–‡ç»é¡¯ç¤ºå¤šé …ç ”ç©¶å·²æ¢è¨æ­¤æ‡‰ç”¨ã€‚</p>

<h3>ç›¸é—œæ–‡ç»</h3>

<table>
<thead>
<tr>
<th>PMID</th>
<th>å¹´ä»½</th>
<th>é¡å‹</th>
<th>æœŸåˆŠ</th>
<th>ä¸»è¦ç™¼ç¾</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/39164577/">39164577</a></td>
<td>2025</td>
<td>Journal Article</td>
<td>Heart and vessels</td>
<td>Bolus ISDN æ³¨å°„å¯é™ä½ mPAPï¼Œåœ¨å¾Œæ¯›ç´°è¡€ç®¡æ€§è‚ºé«˜å£“æ•ˆæœè¼ƒä½³</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/6423015/">6423015</a></td>
<td>1984</td>
<td>Comparative Study</td>
<td>Bull Eur Physiopathol Respir</td>
<td>ISDN å’Œ NTG å‡å¯é™ä½ COPD æ‚£è€…è‚ºå‹•è„ˆå£“</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/28810603/">28810603</a></td>
<td>2017</td>
<td>Journal Article</td>
<td>Exp Ther Med</td>
<td>æ°£ç®¡å…§ ISDN å¯æ”¹å–„å¿ƒè‚Œæ¢—å¡å¾Œå¿ƒè¡°å¤§é¼ çš„è‚ºå‹•è„ˆå£“å’Œå¿ƒå®¤é‡å¡‘</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/373940/">373940</a></td>
<td>1979</td>
<td>RCT</td>
<td>Clin Pharmacol Ther</td>
<td>å£æœ ISDN æœ‰æ•ˆé™ä½ COPD æ‚£è€…è‚ºé«˜å£“</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/3409916/">3409916</a></td>
<td>1988</td>
<td>Journal Article</td>
<td>Eur Heart J</td>
<td>å…©å¹´ ID æ²»ç™‚å¯é•·æœŸæ¸›å°‘é–“è³ªæ€§è‚ºçº–ç¶­åŒ–æ‚£è€…çš„è‚ºé«˜å£“</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/7125407/">7125407</a></td>
<td>1982</td>
<td>Comparative Study</td>
<td>Ann Intern Med</td>
<td>ISDN æ˜¯å”¯ä¸€èƒ½é™ä½åŸç™¼æ€§è‚ºé«˜å£“è‚ºå‹•è„ˆå£“çš„è—¥ç‰©</td>
</tr>
</tbody>
</table>

<p>æ–‡ç»è­‰æ“šé¡¯ç¤º ISDN å°å¤šç¨®é¡å‹çš„è‚ºé«˜å£“ï¼ˆåŒ…æ‹¬ COPD ç›¸é—œã€å¿ƒè¡°ç›¸é—œå’ŒåŸç™¼æ€§è‚ºé«˜å£“ï¼‰å‡æœ‰é™å£“æ•ˆæœã€‚</p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. congenital hypotrichosis milia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. hypotrichosis simplex of the scalp</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. pulmonary hypertension</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39164577/" target="_blank">39164577</a></td><td>2025</td><td>Article</td><td>Heart and vessels</td><td>The effects of bolus isosorbide dinitrate on pulmonary hyper...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/6423015/" target="_blank">6423015</a></td><td>1984</td><td>Article</td><td>Bulletin europeen de</td><td>Nitroglycerin and isosorbide dinitrate in pulmonary hyperten...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28810603/" target="_blank">28810603</a></td><td>2017</td><td>Article</td><td>Experimental and the</td><td>Intratracheal administration of isosorbide dinitrate improve...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2498122/" target="_blank">2498122</a></td><td>1989</td><td>Article</td><td>Experimental and mol</td><td>Comparative effects of isosorbide dinitrate, prednisolone, i...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/373940/" target="_blank">373940</a></td><td>1979</td><td>Article</td><td>Clinical pharmacolog</td><td>Effects of isosorbide dinitrate on pulmonary hypertension in...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. diffuse alopecia areata</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. vascular disease</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.97%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ49 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02045459" target="_blank">NCT02045459</a></td><td>NA</td><td>COMPLETED</td><td>79</td><td>Assessment of Perfusion Reserve and Effects of Exercise in Microvascular Angina</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00803634" target="_blank">NCT00803634</a></td><td>PHASE3</td><td>COMPLETED</td><td>117</td><td>A Safety and Efficacy Study of Blood Pressure Control in Acute Heart Failure - A...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03011775" target="_blank">NCT03011775</a></td><td>PHASE4</td><td>COMPLETED</td><td>43</td><td>Effect of Pioglitazone on Insulin Resistance, Progression of Atherosclerosis and...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01676207" target="_blank">NCT01676207</a></td><td>N/A</td><td>COMPLETED</td><td>120</td><td>Prevalence of Extracardiac Coronary Collateral Supply Via the Internal Mammary A...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04317846" target="_blank">NCT04317846</a></td><td>NA</td><td>COMPLETED</td><td>165</td><td>TransRadIal Evaluation STudy of diamEter Increase After Vasodilatory Drugs Admin...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 44 é …è©¦é©—</em></p>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/9951954/" target="_blank">9951954</a></td><td>1999</td><td>Article</td><td>Drugs</td><td>Long-acting isosorbide mononitrate.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/3925742/" target="_blank">3925742</a></td><td>1985</td><td>Article</td><td>American heart journ</td><td>Nitrate tolerance.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/1576038/" target="_blank">1576038</a></td><td>1992</td><td>Article</td><td>AACN clinical issues</td><td>Nitrates.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2113003/" target="_blank">2113003</a></td><td>1990</td><td>Article</td><td>European journal of </td><td>Nitrates: why and how should they be used today? Current sta...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/7873466/" target="_blank">7873466</a></td><td>1994</td><td>Article</td><td>Cardiovascular drugs</td><td>Clinical pharmacokinetics of nitrates.</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. hypertrichosis (disease)</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.97%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. kyphoscoliotic heart disease</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.96%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. visceral calciphylaxis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.96%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. arterial thoracic outlet syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.95%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| å¤šå¼µè¨±å¯è­‰ | å¯Œåˆ©å¿ƒèˆŒä¸‹éŒ ç­‰ | èˆŒä¸‹éŒ /éŒ åŠ‘ | é é˜²ç‹¹å¿ƒç—‡ç™¼ä½œã€å† ç‹€å‹•è„ˆä¸å…¨ã€å¿ƒçµç—› |

## å®‰å…¨æ€§è€ƒé‡

**å¸¸è¦‹å‰¯ä½œç”¨ï¼š**
- é ­ç—›ï¼ˆæœ€å¸¸è¦‹ï¼‰
- é ­æšˆ
- ä½è¡€å£“
- è‡‰éƒ¨æ½®ç´…
- å¿ƒè·³åŠ é€Ÿ

**ç¦å¿Œç—‡ï¼š**
- èˆ‡ PDE5 æŠ‘åˆ¶åŠ‘ï¼ˆå¦‚ sildenafilï¼‰ä½µç”¨ï¼šå¯èƒ½å°è‡´åš´é‡ä½è¡€å£“
- åš´é‡ä½è¡€å£“
- å³å¿ƒå®¤æ¢—å¡
- è‚¥åšæ€§å¿ƒè‚Œç—…è®Šä¼´æµå‡ºé“é˜»å¡

**é‡è¦è­¦å‘Šï¼š**
è‚ºé«˜å£“æ‚£è€…ä½¿ç”¨æ™‚å¯èƒ½å°è‡´å…¨èº«æ€§ä½è¡€å£“å’Œå¿ƒè¼¸å‡ºé‡ä¸‹é™ï¼Œéœ€è¬¹æ…ç›£æ¸¬ã€‚


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**é’å…‰çœ¼** ğŸ”´ Major
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚

**Cardiomyopathy, Hypertrophic** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šOrganic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients w...

**Myocardial Infarction** ğŸŸ¢ Minor
- ä¸æ‡‰ä½¿ç”¨æœ¬è—¥ç‰©ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šä½è¡€å£“ã€‚

**Anemia** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚é¢¨éšªåŒ…æ‹¬ï¼šè²§è¡€ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**Diseases requiring hemodialysis** ğŸŸ¢ Minor
- é¢¨éšªåŒ…æ‹¬ï¼šä½è¡€å£“ã€‚å¯èƒ½å±åŠç”Ÿå‘½ã€‚

**ä½è¡€å£“** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šä½è¡€å£“ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**Intracranial Hypertension** ğŸŸ¢ Minor
- é¢¨éšªåŒ…æ‹¬ï¼šå‡ºè¡€ã€‚

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**é…’ç²¾** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šç”¢ç”Ÿå”åŒä½œç”¨ã€‚
- å»ºè­°ï¼šå»ºè­°é¿å…ä½µç”¨ã€‚éœ€ç›£æ¸¬ç™‚æ•ˆæˆ–ä¸è‰¯åæ‡‰ã€‚


## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šExplore**

**ç†ç”±ï¼š**
ISDN å°è‚ºé«˜å£“çš„æ²»ç™‚å…·æœ‰æ¸…æ™°çš„è—¥ç†æ©Ÿè½‰å’Œè±å¯Œçš„æ–‡ç»æ”¯æŒã€‚å¤šé …ç ”ç©¶é¡¯ç¤ºå®ƒèƒ½æœ‰æ•ˆé™ä½è‚ºå‹•è„ˆå£“åŠ›ã€‚ç„¶è€Œï¼Œå…¨èº«æ€§è¡€ç®¡æ“´å¼µä½œç”¨å¯èƒ½é™åˆ¶å…¶åœ¨å‰æ¯›ç´°è¡€ç®¡æ€§è‚ºé«˜å£“çš„æ‡‰ç”¨ã€‚ç›®å‰è‚ºå‹•è„ˆé«˜å£“çš„æ¨™æº–æ²»ç™‚å·²æœ‰æ›´é¸æ“‡æ€§çš„è—¥ç‰©ï¼ˆå¦‚å‰åˆ—ç’°ç´ é¡ä¼¼ç‰©ã€PDE5 æŠ‘åˆ¶åŠ‘ï¼‰ï¼ŒISDN å¯èƒ½æ›´é©åˆä½œç‚ºè¼”åŠ©æ²»ç™‚æˆ–ç‰¹å®šäºç¾¤çš„æ›¿ä»£é¸æ“‡ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- æ˜ç¢º ISDN åœ¨ä¸åŒé¡å‹è‚ºé«˜å£“ä¸­çš„å®šä½
- èˆ‡ç¾æœ‰æ¨™æº–æ²»ç™‚çš„æ¯”è¼ƒç ”ç©¶
- ç¢ºå®šæœ€ä½³çµ¦è—¥é€”å¾‘ï¼ˆå¸å…¥ vs å£æœ vs éœè„ˆï¼‰
- é•·æœŸå®‰å…¨æ€§å’Œè€å—æ€§æ•¸æ“š

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Dronedarone]({{ "/drugs/dronedarone/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Hydroxyprogesterone Caproate]({{ "/drugs/hydroxyprogesterone_caproate/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Regorafenib]({{ "/drugs/regorafenib/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Hydroxyurea]({{ "/drugs/hydroxyurea/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Prednisone]({{ "/drugs/prednisone/" | relative_url }}) - è­‰æ“šç­‰ç´š L2

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Isosorbide Dinitrateè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/isosorbide_dinitrate/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_isosorbide_dinitrate,
  title = {Isosorbide Dinitrateè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/isosorbide_dinitrate/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
